Insider Trends: ChemoCentryx Sees Insider Buy Interrupting 90-Days of Sells
07:50 PM EDT, 05/10/2021 (MT Newswires) -- Tausif Butt, EVP, Chief Operating Officer, on May 07, 2021, made a purchase of 10,870 shares in ChemoCentryx (CCXI) for $120,241. Butt, subsequent to the transactions designated in the SEC Form 4 filing, owns 10,870 company shares, with a market value, based on the prior-day closing price, of $113,700.
During the most recent 90-day period, previous to the date of this filing, there have been 10 insider transactions reported to the SEC for ChemoCentryx. These transactions came from the activities of 5 different insiders that resulted in a net disposition of 28,159 company shares. In the preceding 90-day window of time, there were 20 transactions from 5 insiders and resulted in the net acquisition of 18,737 shares.
This is lower than the average level of insider transactions in the 55-company Biopharmaceuticals peer group over the last 90-day period. Activity in the peer group averaged 52.3 transactions per company, with company insiders acquiring on average 139,259 shares.
SEC Story Link http://www.sec.gov/Archives/edgar/data/1340652/000120919121031435/xslF345X03/doc4.xml
This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.